Both in a small study of 16 patients (28), and in a placebo-controlled phase II clinical trial of 186 patients (29) with mild to moderate SLE, TCZ (28) and another IL-6 monoclonal antibody (29) produced a significant dose-related reduction in basal complement levels. The gene discussed is IL6; the disease is systemic lupus erythematosus.